Shares of telehealth provider Hims & Hers Health experienced a dramatic two-day rally, climbing roughly 49% after the company announced a significant distribution partnership with pharmaceutical giant Novo Nordisk. The stock closed at $23.47 on Tuesday, March 11, 2026, marking a 5.9% gain for the session and building on a substantial surge from its close of $15.74 on March 6.
Deal Details and Legal Resolution
The newly forged agreement with Novo Nordisk will see the branded weight-loss medications Ozempic and Wegovy added to the Hims & Hers platform by the end of March. These drugs will be offered at Novo Nordisk's established self-pay rates. As a central component of the pact, Novo Nordisk has withdrawn its previously filed lawsuit against Hims & Hers, removing a significant overhang for the company, though the pharmaceutical firm retains the right to reinstate the legal action if necessary.
Concurrently, Hims & Hers will phase out advertising for most compounded GLP-1 medications. The company will only continue offering compounded semaglutide for a limited subset of patients whose healthcare providers deem it medically necessary. This strategic shift moves the company's weight-loss offering away from pharmacy-mixed treatments and toward FDA-approved branded drugs.
Analyst Reaction and Revised Targets
The announcement triggered a wave of analyst rating adjustments and price target increases. Needham analyst Ryan MacDonald upgraded the stock to Buy, assigning a $30 price target and describing the deal as a "fundamental" shift for the company's weight-loss business. Citi's Daniel Grosslight moved his rating from Sell to Neutral with a $24 target, while Bank of America's Allen Lutz similarly upgraded to Neutral from Underperform, setting a $23 target. Deutsche Bank's George Hill maintained his existing recommendation but raised his price target to $28.
Analysts highlighted that the agreement mitigates the most pressing legal risk facing the company. BTIG's David Larsen noted that Novo Nordisk had a strong legal case, and the settlement reduces potential regulatory exposure from agencies like the FDA or the Department of Justice. Truist analyst Jailendra Singh pointed to a relationship of "mutual necessity" between the two companies.
Market Context and Competitive Landscape
The partnership arrives amid intense competition in the obesity drug market, where Novo Nordisk faces a formidable challenge from Eli Lilly. According to Novo Nordisk's Mike Doustdar, telehealth collaborations are accelerating the rollout of medications like the Wegovy pill, which garnered over 600,000 prescriptions in a two-month period. In a related move to boost accessibility, Novo Nordisk has also significantly reduced website prices for its weight-loss drugs, lowering costs from approximately $1,000 per month to a range between $149 and $299.
Potential Challenges and Margin Concerns
Despite the bullish stock reaction, analysts caution that the transition presents financial complexities. While branded products are expected to boost overall revenue, they typically carry lower margins compared to compounded drugs. Analysis from Citi suggests Hims & Hers may need to secure about 70% more subscriptions for branded drugs to offset the revenue lost from scaling back compounded sales. Deutsche Bank also noted unresolved questions regarding pricing and execution remain.
Regulatory and Growth Outlook
Regulatory scrutiny continues to be a factor for Hims & Hers. The company was informed in February of an investigation by the Securities and Exchange Commission. Furthermore, analysts warn that new expenses related to U.S. operations and international expansion could complicate the financial outlook for 2026, a year in which growth is already projected to slow. The company has forecast revenue growth exceeding 15% for the year, following a 59% surge reported for 2025.
The core debate among investors has now shifted. The focus is no longer on Hims & Hers' ability to scale its business, which is largely assumed, but rather on whether the company can grow sales of the new branded drugs rapidly enough to compensate for the thinner margins on each prescription. The market will be closely watching the execution of this strategic pivot in the coming quarters.
